Chemsex Engagement and HIV Biomedical Prevention in MSM

Recreational Drug Use Clinical Trial

Official title:

The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05031832
• Other study ID #: MSS344R
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: September 2023
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2024
• Est. primary completion date: May 4, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• aged 18 or above
• male
• have had sex with men since 2019
• could be communicated in English or Chinese

Exclusion Criteria:

• failed to provide consent

Related Conditions & MeSH terms

• Recreational Drug Use

Intervention

Diagnostic Test:
• HIV test
HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status

Locations

Country	Name	City	State
Hong Kong	The Chinese University of Hong Kong	Hong Kong	Hong Kong, China

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pre-exposure prophylaxis coverage	proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire	6 months
Primary	Good antiretroviral therapy adherence	proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire	2 years
Primary	Drug use pattern	types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire	6 months